Groesbeck Investment Management Corp NJ Takes Position in Edwards Lifesciences Co. (NYSE:EW)

Groesbeck Investment Management Corp NJ bought a new stake in Edwards Lifesciences Co. (NYSE:EW) in the fourth quarter, Holdings Channel reports. The institutional investor bought 2,700 shares of the medical research company’s stock, valued at approximately $200,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. FSA Wealth Management LLC purchased a new position in Edwards Lifesciences in the third quarter valued at about $30,000. Prospera Private Wealth LLC purchased a new position in Edwards Lifesciences in the third quarter valued at about $32,000. Avior Wealth Management LLC increased its holdings in Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after buying an additional 308 shares in the last quarter. JFS Wealth Advisors LLC increased its holdings in Edwards Lifesciences by 31.1% in the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock valued at $46,000 after buying an additional 166 shares in the last quarter. Finally, Roble Belko & Company Inc purchased a new position in Edwards Lifesciences in the fourth quarter valued at about $46,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total value of $327,850.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at $3,077,593.52. The trade was a 9.63 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Daniel J. Lippis sold 2,500 shares of the business’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $74.08, for a total transaction of $185,200.00. Following the completion of the transaction, the vice president now owns 23,189 shares in the company, valued at $1,717,841.12. This represents a 9.73 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 8,000 shares of company stock worth $547,430. 1.27% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Stock Down 0.1 %

Shares of NYSE EW opened at $71.33 on Wednesday. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $42.07 billion, a PE ratio of 10.29, a P/E/G ratio of 3.72 and a beta of 1.11. The firm has a fifty day moving average of $72.49 and a 200-day moving average of $69.63. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12.

Analyst Upgrades and Downgrades

EW has been the subject of a number of research analyst reports. Sanford C. Bernstein raised shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. Citigroup increased their price target on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Canaccord Genuity Group increased their price target on shares of Edwards Lifesciences from $63.00 to $68.00 and gave the company a “hold” rating in a research report on Thursday, December 5th. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and increased their price target for the company from $82.00 to $90.00 in a research report on Monday, December 16th. Finally, Wolfe Research lowered shares of Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price target on the stock. in a research report on Thursday, January 16th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, Edwards Lifesciences currently has a consensus rating of “Hold” and a consensus target price of $79.19.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.